Stocktoria
KALA BIO, Inc. KALA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-07-20
KALA BIO, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M | $6.4M | $6.1M | — | $0 | $0 |
| R&D expense | — | — | — | — | — | $18.4M | $27.3M | $29.3M | $29.0M | $25.0M |
| SG&A expense | — | — | $20.6M | $65.0M | $105.1M | $81.1M | $65.0M | $35.4M | $10.9M | — |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M | -$130.2M | -$96.2M | -$88.2M | -$64.7M | -$39.9M | -$32.7M |
| Interest expense | — | — | $5.8M | $7.3M | $8.4M | $8.6M | $8.5M | $3.3M | $1.0M | $767,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | -$142.6M | -$104.3M | -$94.3M | -$66.7M | -$42.2M | -$33.2M |
| EPS (diluted) | $-3.31 | $-10.15 | $-17.35 | $-29.48 | $-108.32 | $-1.99 | — | — | — | — |
| Operating cash flow | -$32.0M | -$29.4M | -$27.9M | -$78.9M | -$108.2M | -$90.7M | -$92.7M | -$54.1M | -$34.1M | -$27.3M |
| Free cash flow | — | — | — | — | — | — | -$94.1M | -$55.7M | -$34.6M | -$27.5M |
| Cash & equivalents | $7.6M | $51.2M | $50.9M | $70.5M | $92.1M | $77.3M | $85.4M | — | — | $45.5M |
| Inventory | — | — | — | — | $8.6M | $5.2M | $4.6M | $4.1M | — | — |
| Total assets | $9.5M | $55.5M | $55.9M | $86.8M | $139.4M | $221.6M | $154.3M | $221.0M | $116.5M | $46.3M |
| Total liabilities | $2.5M | $43.2M | $48.4M | $67.8M | $122.6M | $121.6M | $124.6M | $116.0M | $26.9M | $15.7M |
| Shareholders' equity | $7.0M | $12.3M | $7.5M | $19.0M | $16.8M | $100.0M | $29.7M | $105.0M | $89.7M | -$87.8M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | -65.4% | +76.7% | +4.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.